Title: MCM6 is a Poor Prognostic Biomarker and Promotes Progression in Breast Cancer
Authors: Zi Lei, Peng Wang, Da-qi Jia, Lei-lei Li, Yi-peng Wu, Yuan Yang, Guo-qing Pan, Taeg Kyu Kwon
Section: 3.6 MCM6 Knockdown Inhibited the Proliferation of Breast Cancer Cells
progression of KRAS mutant lung adenocarcinoma by pro- moting SLC7A5 translation. Frontiers in Oncology. 2022; 12: 1043177. [26] Tsimberidou AM. Targeted therapy in cancer. Cancer Chemotherapy and Pharmacology. 2015; 76: 1113–1132. [27] Diéras V, Bachelot T. The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer. Targeted Oncology. 2014; 9: 111–122. [28] Silva AS, Kam Y, Khin ZP, Minton SE, Gillies RJ, Gatenby RA. Evolutionary approaches to prolong progression-free survival in breast cancer. Cancer Research. 2012; 72: 6362–6370. [29] Kwok HF, Zhang SD, McCrudden CM, Yuen HF, Ting KP, Wen Q, et al. Prognostic significance of minichromosome maintenance proteins in breast cancer. American Journal of Cancer Research. 2014; 5: 52–71. [30] Sadeghian D, Saffar H, Mahdavi Sharif P, Soleimani V, Jahanbin B. MCM6 versus Ki-67 in diagnosis of luminal molecular subtypes of breast cancers. Diagnostic Pathology. 2022; 17: 24. [31] Liu Z, Li J, Chen J, Shan Q, Dai H, Xie H, et al. MCM family in HCC: MCM6 indicates adverse tumor features and poor outcomes and promotes S/G2 cell cycle progression. BMC Cancer. 2018; 18: 200. [32] Chen QY, Liu LC, Wang JB, Xie JW, Lin JX, Lu J, et al. CDK5RAP3 Inhibits the Translocation of MCM6 to Influence the Prognosis in Gastric Cancer. Journal of Cancer. 2019; 10: 4488–4498. [33] Liu D, Zhang XX, Xi BX, Wan DY, Li L, Zhou J, et al. Sine oculis homeobox homolog 1 promotes DNA replication and cell proliferation in cervical cancer. International journal of oncology. 2014; 45: 1232–1240. [34] Boulay PL, Schlienger S, Lewis-Saravalli S, Vitale N, Ferbeyre G, Claing A. ARF1 controls proliferation of breast cancer cells by regulating the retinoblastoma protein. Oncogene. 2011; 30: 3846–3861. [35] Sherman DA, Pasion SG, Forsburg SL. Multiple domains of fission yeast Cdc19p (MCM2) are required for its association with the core MCM complex. Molecular Biology of the Cell. 1998; 9: 1833–1845. [36] Liu M, Liu H, Chen J. Mechanisms of the CDK4/6 inhibitor palbociclib (PD 0332991) and its future application in cancer treatment (Review). Oncology Reports. 2018; 39: 901–911. [37] Tanaka Y, Momose S, Tabayashi T, Sawada K, Yamashita T, Higashi M, et al. Abemaciclib, a CDK4/6 inhibitor, exerts preclinical activity against aggressive germinal center-derived B-cell lymphomas. Cancer Science. 2020; 111: 749–759. [38] Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptorpositive human breast cancer cell lines in vitro. Breast Cancer Research: BCR. 2009; 11: R77. [39] Zeiser R,